<DOC>
	<DOCNO>NCT02404532</DOCNO>
	<brief_summary>The purpose study determine accuracy IEM detection MIND1 System complete series Patch application IEM ingestion clinic .</brief_summary>
	<brief_title>Substudy ' B ' Accuracy Ingestible Event Marker ( IEM ) Detection Medical Information Device # 1 ( MIND1 )</brief_title>
	<detailed_description>The OSMITTER study protocol design master protocol govern multiple substudies rapid assessment candidate subcomponents MIND1 System . This substudy conduct determine accuracy IEM detection MIND1 System complete series Patch application IEM ingestion clinic . Following placement Patch clinic staff , subject ingest one placebo-embedded IEM tablet approximately every hour , total 4 ingestion . Placebo-embedded IEM tablet test measure accuracy IEM detection MIND1 system . Approximately 30 healthy volunteer subject enrol substudy . The duration substudy Visit 1 ( Day 1 ) safety follow-up approximately 1 week , approximately 1 day allot active subject participation , plus 1-week safety follow-up period .</detailed_description>
	<criteria>Healthy male healthy nonpregnant female 18 65 year age time informed consent willing either practice abstinence 2 barrier method birth control 1 barrier method oral contraceptive method . Subject must good general health ( suffer serious chronic mental physical disorder require may near future require urgent medical care ) . Body mass index 19 32 kg/m2 ( inclusive ) . Subject history skin sensitivity adhesive medical tape metal . Subject history evidence medical condition would expose undue risk significant adverse event ( AE ) interfere assessment safety course trial . Subject receive investigational product within last 30 day . Subject current history drug alcohol dependence meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion . Subject presence cognitive impairment . Subject currently take antipsychotic medication . Subject terminal illness . Subject history chronic dermatitis . Subject history gastrointestinal surgery could impair absorption . Female subject breastfeed and/or positive serum pregnancy test result prior receive trial medication . Sexually active woman childbearing potential ( WOCBP ) commit use 2 form approve birth control method remain abstinent trial 30 day follow last dose trial medication . Sexually active male commit use 2 approved birth control method remain abstinent duration trial 90 day follow last dose trial medication . No permanent physical residence . A diastolic blood pressure read &gt; 95 mm Hg symptomatic hypotension . Any subject , opinion investigator , participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>OPC-14597 Digital</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Medical Information Device # 1 System ( MIND1 )</keyword>
	<keyword>Ingestible Event Marker</keyword>
</DOC>